Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS

Completed · Phase 3 · Has a placebo group

Conditions studied: Acute Coronary Syndrome

In brief

A placebo-controlled, randomized, double-blind, parallel group, phase III multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. Subject enrollment may begin in the hospital and will continue following release from the hospital. Screening procedures may be performed at the time of the index ACS event or anytime thereafter, with the condition that randomization must occur within the mandated window (4-12 weeks after the index event). Subjects will be assessed based on their medical history. Those who are likely to qualify will undergo Genotype Assay testing to evaluate genetic determination for the presence of AA genotype.

Key facts

Study ID

NCT02525939

Run by

DalCor Pharmaceuticals

People needed

6147

Starts

2016-04-01

Expected to finish

2021-10-01

Last updated by the study team

2022-10-12

Who can join

Age: 45 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with the appropriate genetic background and recently hospitalized for ACS (between 4 and 12 weeks following the index event), will be enrolled in this trial.
• AA genotype at variant gene as determined by Genotype Assay testing, conducted at a designated investigational testing site (ITS)
• Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization
• Prior to randomization, subject must have evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment to a target level of LDL-C <100 mg/dl (<2.6 mmol/L).

You may not qualify if…

• Females who are pregnant (negative pregnancy test required for all women of child-bearing potential at Visit 2, Day 0) or breast-feeding
• Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who are not using at least one method of contraception*
• New York Heart Association (NYHA) Class III or IV heart failure
• Last known hemoglobin <10 g/dL
• Index ACS event presumed due to uncontrolled hypertension
• (*) Varies by region

Where it is running

• Research Site — Huntsville, Alabama, United States
• Research Site — Mobile, Alabama, United States
• Research Site — Cottonwood, Arizona, United States
• Research Site — Glendale, Arizona, United States
• Research Site — Jonesboro, Arkansas, United States
• Research Site — Huntington Beach, California, United States
• Research Site — San Diego, California, United States
• Research Site — Torrance, California, United States
• Research Site — Denver, Colorado, United States
• Research Site — Littleton, Colorado, United States
• Research Site — Danbury, Connecticut, United States
• Research Site — Hartford, Connecticut, United States
• Research Site — Washington D.C., District of Columbia, United States
• Research Site — Clearwater, Florida, United States
• Research Site — Daytona Beach, Florida, United States
• Research Site — Fort Lauderdale, Florida, United States
• Research Site — Gainesville, Florida, United States
• Research Site — Homestead, Florida, United States
• Research Site — Hudson, Florida, United States
• Research Site — Jacksonville, Florida, United States
• Research Site — Largo, Florida, United States
• Research Site — Miami, Florida, United States
• Research Site — Miramar, Florida, United States
• Research Site — Orlando, Florida, United States
• Research Site — Alexander City, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.